GAMMA Investing’s Innate Pharma IPHA Stock Holding History

GAMMA Investing’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15	Hold	9	–	–	﹤0.01%	4320
2026 Q2	$17	Sell	9 -231	-96%	-$382	﹤0.01%	4130
2026 Q1	$307	Sell	240 -833	-78%	-$1.36K	﹤0.01%	4020
2025 Q4	$1.88K	Sell	1,073 -1,208	-53%	-$2.33K	﹤0.01%	3621
2025 Q3	$4.4K	Sell	2,281 -1,175	-34%	-$2.36K	﹤0.01%	3226
2025 Q2	$6.27K	Buy	3,456 +1,223	+55%	+$2.48K	﹤0.01%	3029
2025 Q1	$3.98K	Buy	+2,233	New	+$4.36K	﹤0.01%	3174

Other funds holding IPHA

SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's IPHA Position: Q3 2026 in Review

GAMMA Investing held its Innate Pharma (IPHA) position steady in Q3 2026 at 9 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #4320.

GAMMA Investing first reported a position in IPHA in Q1 2025 and has held it in 7 quarters since. The position peaked at $6.27K in Q2 2025. 4 funds tracked by Wall St. Rank hold IPHA as of Q3 2026.

GAMMA Investing held 9 shares of Innate Pharma worth $15 as of Q3 2026.
GAMMA Investing left its Innate Pharma share count unchanged in Q3 2026.
Innate Pharma made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4320 holding.
GAMMA Investing first reported a position in Innate Pharma in Q1 2025 and has held it in 7 quarters since.
GAMMA Investing's Innate Pharma position peaked at $6.27K in Q2 2025.
4 funds tracked by Wall St. Rank held Innate Pharma as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.